Quest Diagnostics (DGX) Tops Q3 EPS by 4c

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $1.39, $0.04 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.92 billion.

GUIDANCE:

Quest Diagnostics sees FY2017 EPS of $5.62-$5.67, versus the consensus of $5.63. Quest Diagnostics sees FY2017 revenue of $7.71 billion, versus the consensus of $7.69 billion.

"We delivered another strong quarter of revenue growth in spite of weather challenges, completed two previously announced acquisitions, and agreed to purchase Shiel Medical Laboratory," said Steve Rusckowski, Chairman, President and CEO. "Yesterday we also announced a strategic relationship with Cleveland Clinic that includes the acquisition of Cleveland HeartLab. Our two-point strategy of accelerating growth and driving operational excellence is producing results. Our updated guidance for full year 2017 primarily reflects the impact of hurricanes in the third quarter which impacted geographies where we have a large presence as well as recently closed acquisitions."

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Oilfield firm SLB's profit rises on international drilling demand
• Schlumberger (SLB) earnings in-line, revenue beats expectations